Colossal Biosciences, the Dallas-based de-extinction startup valued at over $10 billion after its $200 million Series C in January 2025, is now presenting itself as a live demonstration of AI-driven genomics moving species revival from theory into living animals.[1] The company reported woolly mice in 2025 and, in April 2026, three dire wolf pups — Romulus, Remus, and Khaleesi — carrying revived genes from the extinct Aenocyon dirus, which disappeared more than 10,000 years ago.[1] The article says the next targets are the woolly mammoth, dodo, and thylacine, with first mammoth calves still targeted for 2028.[1]
Technically, the shift is not simple resurrection but a pipeline that combines ancient DNA reconstruction, multiplex gene editing, synthetic surrogacy, stem-cell platforms, and AI-enabled ecological modelling.[1][2] That combination matters for lunar habitation because it signals faster design cycles for complex genomes, higher-fidelity trait reconstruction, and better control over breeding, conservation, and bioengineering workflows under constrained environments.[1][2][3] For existential risk planning, it also shows that advanced biotechnology is becoming modular and commercially scalable, which increases both the recovery potential for damaged biospheres and the misuse risk for engineered organisms.[1][3]
The Ark team should track three developments: AI methods for ancient DNA reconstruction, ex-utero or synthetic gestation systems, and the commercialization timeline for mammoth, dodo, and thylacine projects.[1][2][5] The team should also map which conservation-grade genomic tools are transferable to closed-loop life support, cryobanking, and species restoration after planetary catastrophe.[2][3][8] Priority research should focus on whether these platforms can preserve functional biodiversity, not just recreate headline species, because ecosystem resilience is the real civilizational asset.[2][3][5]